Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials

AIM: To investigate the efficacy and safety of initiating insulin degludec/liraglutide (IDegLira) in patients with type 2 diabetes (T2D) who had discontinued pretrial sulphonylureas (SUs) or dipeptidyl peptidase‐4 inhibitors (DPP4is) versus patients not previously treated with these regimens. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales: Janez, Andrej, Őrsy, Petra, Stachlewska, Karolina, Salvesen‐Sykes, Karen, Billings, Liana K., Philis‐Tsimikas, Athena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079143/
https://www.ncbi.nlm.nih.gov/pubmed/31858673
http://dx.doi.org/10.1111/dom.13944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079143/
https://www.ncbi.nlm.nih.gov/pubmed/31858673
http://dx.doi.org/10.1111/dom.13944

Ejemplares similares